<DOC>
	<DOCNO>NCT01769001</DOCNO>
	<brief_summary>Patients enrol one three PRX-102 dose group ( 0.2 mg/kg , 1.0 mg/kg , 2.0 mg/kg ) , receive dose receive Phase 1/2 study PB-102-F01 , continue receive PRX-102 intravenous infusion every 2 week 38 week .</brief_summary>
	<brief_title>An Extension Phase 1/2 , Open Label , Dose Ranging Study PRX-102 Adult Fabry Patients</brief_title>
	<detailed_description>Patients enrol one three PRX-102 dose group ( 0.2 mg/kg , 1.0 mg/kg , 2.0 mg/kg ) receive dose receive Phase 1/2 study , PB-102-F01 , continue receive intravenous infusion PRX-102 every 2 week 38 week ( 9 month ) . All exploratory endpoint evaluate Phase 1/2 study PB-102-F01 continue assess extension protocol ( study PB-102-F02 ) . The additional exploratory efficacy parameter evaluate baseline Phase 1/2 study PB-102-F01 reference point , initiation treatment , evaluate 3 month extension study ( total treatment 6 month ) . These parameter include Gb3 concentration renal skin tissue , LVM , MSSI cardiac function test ( echocardiography stress test ) . Cerebrovascular disease ( clinical MRI ) evaluate last infusion ( total treatment 12 month ) .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Completion Phase 1/2 study PB102F01 The patient sign inform consent Female patient male patient whose copartner childbearing potential agree use medically acceptable method contraception , include rhythm method Pregnant nursing Presence medical , emotional , behavioral psychological condition , judgment Investigator and/or Medical Director , would interfere patient 's compliance requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fabry disease</keyword>
	<keyword>Alpha galactosidase deficiency</keyword>
	<keyword>Metabolic storage disease</keyword>
</DOC>